-
Japan approves Merck's Keytruda to treat breast and colorectal cancer
Time of Update: 2021-09-13
In the randomized, placebo-controlled phase 3 KEYNOTE-355 (NCT02819518) trial, compared with the placebo combined chemotherapy group, the risk of disease progression or death in the Keytruda combined chemotherapy group was significantly reduced by 35%, and progression-free survival (PFS) Showing a statistically significant and clinically significant prolongation (9.
-
Takeda Vonolasen is about to be approved for new indications, P-CABs intensify competition in the domestic acid suppressant market
Time of Update: 2021-09-13
In February 2015, the drug was approved in Japan for the treatment of acid-related diseases, including reflux esophagitis, gastric ulcer, duodenal ulcer, and prevention during treatment with low-dose aspirin or non-steroidal anti-inflammatory drugs Recurrence of gastric ulcer or duodenal ulcer and eradication of Helicobacter pylori were launched in South Korea in July 2018 .
-
The fifth round of national procurement, implementation time announced
Time of Update: 2021-09-13
HenanHenan On August 31, the Henan Provincial Medical Security Bureau issued the "Notice on Doing a Good Job in the Implementation of the Fifth Batch of National Organized Drug Centralized Procurement and Chongqing Pharmaceutical Procurement Alliance to ensure supply, stable price and quantity procurement .
-
Multinational pharmaceutical companies are digging into the Chinese market and rely on new products to drive growth
Time of Update: 2021-09-13
Western drugmakers such as AstraZeneca, Bayer, Eli Lilly, Merck, Novartis, Novo Nordisk and Sanofi reported growth in drug sales in China in the first half of 2021 .
In the first half of this year, the company's sales in China increased by 11% at a constant exchange rate to US$3.
-
After the implementation of the new "Physician Law", what are the impacts of the primary medical and health field?
Time of Update: 2021-09-13
That is Article 11 of the "Physician Law": Those who have studied Chinese medicine in the form of a teacher for at least three years, or have proven expertise after years of practicing medical skills, are qualified and recommended by the professional organization of Chinese medicine or medical and health institutions commissioned by the health authorities of the people’s government at or above the county level, and can participate in the qualification examination of Chinese medicine doctors.
-
The market value has doubled: why the pioneering pharmaceutical industry is flying against the wind
Time of Update: 2021-09-13
Due to the discovery that a prostatic drug under research, Prokalamide, may have a potential effect on the treatment of new crowns, the share price of Chinese biotechnology company Kaiyuan Pharmaceutical in Hong Kong stocks has doubled several times, and its market value has soared from HK$6.
-
The first in China! Qilu Pharmaceutical's Disumab Biosimilar Applied for Listing
Time of Update: 2021-09-13
The first and only RANKL inhibitor approved for this indication in China Although Amgen’s original Disulumab injection has a "first-mover" advantage, with Qilu Pharmaceutical's Disulumab biosimilar drug and other latecomers approved, the market space of the former will be squeezed .
-
EQRx: "Introduction" accelerator for overseas innovative drugs
Time of Update: 2021-09-13
However, EQRx, a start-up company established in the United States in early 2020, is committed to making lower-priced innovative drugs quickly accessible in the US market, and may become one of the forces that accelerate the "involution" of overseas innovative drugs .
-
$1.4 billion antithrombotic drug!
Time of Update: 2021-09-13
com's sales database of multinational listed companies According to data from Meinenet, the global sales of Edoxaban have grown steadily in recent years, reaching 154.
-
Junshi Biology's mid-term report released: revenue surged by 268% in the first half of the year, over 40 innovative pipelines attracted attention
Time of Update: 2021-09-13
Also in February of this year, the new crown neutralizing antibody esvirizumab jointly developed by Junshi Biotech and domestic scientific research institutions was granted the US FDA Emergency Use Authorization (EUA).
-
With the most approved indications and the widest coverage of medical insurance, Hengrui Pharmaceuticals strives to promote PD-1 to benefit patients
Time of Update: 2021-09-13
After being included in the provincial special medicine management scope, even if some hospitals have time to introduce carrelizumab and other national anti-cancer drugs in the future, patients in Jiangsu Province can still buy these life-saving drugs from designated special medicine medical insurance pharmacies and enjoy them.
-
Behind the cut-off of supply by pharmaceutical companies: Is the low price of centralized procurement really affecting profits?
Time of Update: 2021-09-13
Regarding North China Pharmaceutical’s breach of contract, the United Procurement Office has stated in its announcement on August 20 that the company’s ibuprofen sustained-release capsules selected in the third batch of nationally organized drug procurement failed to supply the agreed procurement volume in Shandong Province according to the agreement.
-
CSPC's 2 bio-pharmaceuticals have been clinically approved, and domestically produced hepatitis B class 1 new drugs are coming!
Time of Update: 2021-09-13
Zorifertinib tablets The class 1 new drug zorifertinib tablets declared by Chentai Medicine has obtained the implied license of clinical trials, and it is planned to be developed for the treatment of non-small cell lung cancer (NSCLC) .
-
Depth｜Consolidate and absorb the reform achievements, improve the registration and filing system, and welcome new regulations for the management of medical device registration and filing
Time of Update: 2021-09-13
In addition to the commonality with the management of medical device registration and filing, the requirements for the inspection of in vitro diagnostic reagents in different packaging specifications, inspection report requirements, and the use of national standard products Special requirements are put forward in terms of requirements, clinical evaluation and clinical trials .
-
Expanding the immunotherapy pipeline, Baiming Xinkang acquires Aptope assets
Time of Update: 2021-09-13
Apitope's product pipeline focuses on the field of autoimmune diseases, including several innovative drug projects in the clinical, pre-clinical, and research and development stages .
Apitope has developed a series of clinical stage products for antigen-specific immunotherapy, including the treatment of toxic diffuse goiter.
-
Antitrust is really here!
Time of Update: 2021-09-13
Strengthening anti-monopoly and deepening the implementation of fair competition policies are the inherent requirements for improving the socialist market economy system The pharmaceutical industry is a key area of anti-monopoly this year .
-
Dongyangguang Pharmaceutical, Qilu...59 new drugs were approved for clinical trials, Hengrui’s 11th category 1 new drug was submitted for production, and Amgen’s new drug struck
Time of Update: 2021-09-13
3 billion imported blockbuster new drugs are reported for production; Two Class 1 new drugs of Zhengda Tianqing and Cinda were approved for clinical use; New anti-AD drug, the first domestic Tau antibody to apply for clinical application; Kelun, Hausen, CSPC.
-
Gilead vs. Bristol-Myers Squibb's $1.2 billion CAR-T patent case reversed
Time of Update: 2021-09-13
S. Court of Appeals overturned the previous judgment and ruled that Gilead Yescarta does not need to pay Bristol-Myers Squibb the 1.
2 billion CAR-T patent infringement case, the core products and technologies involved are mainly concentrated in Yescarta, a subsidiary of Gilead, and Juno Therapeutics, a subsidiary of Bristol-Myers Squibb, which targets CD19 CAR-T technology .
-
Analysis of 271 drugs competing for the new version of the medical insurance catalogue: The opportunities for listed drugs before 2016 are elusive, and monoclonal antibodies and tinib are still active
Time of Update: 2021-09-13
Outlook: The adjustment of the medical insurance catalog in 2021 is imminent. From the selection direction of the catalog, it can be seen that innovative drugs and new indications will be the main m
-
The second shot of the collection of consumables is about to fire! Will the average drop of these four types of products exceed 80%? How are the rules of one product one policy formulated? Before the market share was less than 30%, can domestic substitution be achieved smoothly?
Time of Update: 2021-09-13
In order to better promote the centralized procurement of artificial joints, on August 26, the State Organization of the Joint Procurement Office of High-Value Medical Consumables conducted a training meeting for participating companies to interpret and answer questions on the procurement documents .
